Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  McLean, Daniel ^a,b   Cooke, Michael J ^a   Wang, Yuanfei ^a,b   Green, David ^c   Fraser, Paul E ^d   George Hyslop, Peter St ^d,e   Shoichet, Molly S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; COPPER 64; MACROGOL; MACROGOL MODIFIED MONOCLONAL ANTIBODY 6E10 TETRAXETAN CONJUGATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6E10 TETRAXETAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; HYPEROSMOLARITY; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; OSMOTIC PRESSURE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RABBITS;

ANIMALIA;

EID: 84871352347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051958     Document Type: Article

References (31)

1. Selkoe DJ, (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handbook of clinical neurology/edited by PJ Vinken and GW Bruyn 89: 245-260.
2. Tam JHK, Pasternak SH, (2012) Amyloid and Alzheimer's Disease: Inside and Out. Canadian Journal of Neurological Sciences 39: 286-298.
3. Bilbul M, Schipper HM, (2011) Risk Profiles of Alzheimer Disease. Canadian Journal of Neurological Sciences 38: 580-592.
4. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, et al. (2011) The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology 95: 718-728.
5. Galvin JE, Sadowsky CH, (2012) Practical guidelines for the recognition and diagnosis of dementia. Journal of the American Board of Family Medicine: JABFM 25: 367-382.
6. Reiman EM, Jagust WJ, (2012) Brain imaging in the study of Alzheimer's disease. Neuroimage 61: 505-516.
7. Chua TC, Wen W, Slavin MJ, Sachdev PS, (2008) Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. Current Opinion in Neurology 21: 83-92 10.1097/WCO.1090b1013e3282f4594b.
8. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, et al. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience 25: 7709-7717.
9. Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology 55: 306-319.
10. Frisoni GB, Giannakopoulos P, (2012) The specificity of amyloid imaging in the diagnosis of neurodegenerative diseases. Neurobiology of Aging 33: 1021-1022.
11. Poduslo JF, Curran GL, Berg CT, (1994) Macromolecular Permeability Across the Blood-Nerve and Blood-Brain Barriers. Proceedings of the National Academy of Sciences of the United States of America 91: 5705-5709.
12. Liu R, Martuza RL, Rabkin SD, (2005) Intracarotid delivery of oncolytic HSV vector G47[Delta] to metastatic breast cancer in the brain. Gene Ther 12: 647-654.
13. Jordao JF, Ayala-Grosso CA, Markham K, Huang YX, Chopra R, et al. (2010) Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-beta Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease. Plos One 5.
14. Boado RJ, Zhang YF, Zhang Y, Xia CF, Pardridge WM, (2007) Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and A beta fibril disaggregation. Bioconjugate Chemistry 18: 447-455.
15. Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, et al. (2008) Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar A beta 42 for magnetic resonance molecular imaging. Pharmaceutical Research 25: 1861-1872.
16. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, et al. (2006) Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. Journal of Pharmacology and Experimental Therapeutics 317: 1246-1253.
17. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, et al. (2011) Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences of the United States of America 108: 18837-18842.
18. Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, et al. (2007) Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cellular and Molecular Life Sciences 64: 356-364.
19. Bjugstad KB, Redmond DE Jr, Lampe KJ, Kern DS, Sladek JR Jr, et al. (2008) Biocompatibility of PEG-based hydrogels in primate brain. Cell Transplant 17: 409-415.
20. McLean D, Cooke MJ, Wang Y, Fraser P, George-Hyslop PS, et al. (2012) Targeting the amyloid-β antibody in the brain tissue of a mouse model of Alzheimer's disease. Journal of Controlled Release 159: 302-308.
21. Sair HI, Doraiswamy PM, Petrella JR, (2004) In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46: 93-104.
22. Bryan JN, Jia F, Mohsin H, Sivaguru G, Anderson CJ, et al. (2011) Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy. Cancer Biology & Therapy 11: 1001-1007.
23. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Journal of Biological Chemistry 276: 21562-21570.
24. Veronese FM, (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22: 405-417.
25. Paul J, Strickland S, Melchor JP, (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. Journal of Experimental Medicine 204: 1999-2008.
26. Wang YF, Cooke MJ, Lapitsky Y, Wylie RG, Sachewsky N, et al. (2011) Transport of epidermal growth factor in the stroke-injured brain. Journal of Controlled Release 149: 225-235.
27. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, et al. (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Research Reviews 27: 119-142.
28. Zhang Y, Wang Y, Boado R, Pardridge W, (2008) Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene Transfer. Pharmaceutical Research 25: 400-406.
29. Skarlatos S, Pardridge WM, (1995) Targeting of an Anti-CR3 (CD11b/CD18) Monoclonal Antibody to Spleen But Not Brain, In Vivo in Mice. Journal of Drug Targeting 3: 9-14.
30. Wisniewski T, Konietzko U, (2008) Amyloid-β immunisation for Alzheimer's disease. The Lancet Neurology 7: 805-811.
31. Boche D, Zotova E, Weller RO, Love S, Neal JW, et al. (2008) Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 131: 3299-3310.